Special Issue

Inflammation and Immunosenescence in Age-Related Diseases

Message from the Guest Editors

Aging is accompanied by the decreased efficacy of the immune system. This has commonly been associated with reduced responses to vaccinations and increased mortality in the elderly. This process is known as immunosenescence, and it affects both innate and adaptive immunity. Age-related inflammation ("inflammaging) plays a determinant role in immunosenescence, and it therefore contributes to the pathogenesis of chronic diseases. The aim of this Special Issue is to decipher the role of inflammation and immunosenescence in age-related diseases. Original papers or reviews aiming at describing the interplay between immune dysfunction, inflammation, and immunosenescence in age-related diseases are welcome for this Special Issue.

Guest Editors

Dr. Luca Pangrazzi

Institute for Biomedical Aging Research, University of Innsbruck, 6020 Innsbruck, Austria

Dr. Magdalena Hagen

Institute for Biomedical Aging Research, University of Innsbruck, Innsbruck, Austria

Deadline for manuscript submissions

closed (31 July 2024)



Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 5.2 Indexed in PubMed



mdpi.com/si/164708

Biomedicines MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 biomedicines@mdpi.com

mdpi.com/journal/

biomedicines





Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 5.2 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

 Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).